|
Results of PROSPECT: A randomized phase 3 trial of PROSTVAC-V/F (PRO) in men with asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer. |
|
|
Research Funding - Astellas Medivation (Inst); Bavarian Nordic (Inst); EMD Serono (Inst); NantBioScience (Inst); Pfizer (Inst) |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Caris Life Sciences |
Honoraria - Pfizer; UpToDate |
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Caris Life Sciences; Fujifilm; Genentech/Roche; HERON; Pfizer; Tolero Pharmaceuticals |
Speakers' Bureau - AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Sanofi |
Research Funding - Endocyte (Inst); Merck (Inst); Suzhou Kintor Pharmaceuticals (Inst); US Oncology (Inst); Viamet Pharmaceuticals (Inst) |
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bayer/Onyx; Exelixis; Genentech/Roche; Pfizer; US Oncology |
|
|
Travel, Accommodations, Expenses - Amgen; Astellas Oncology; GlaxoSmithKline; Novartis; Pfizer |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Cerulean Pharma; Clovis Oncology; Eisai; EMD Serono; Exelixis; Genentech/Roche; Medivation/Astellas; Merck; Nektar; Novartis; Pfizer |
Research Funding - Amgen (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Rexahn Pharmaceuticals (Inst); Takeda (Inst); TRACON Pharma (Inst) |
|
|
Honoraria - Advanced Accelerator Applications; Bayer; Janssen |
Consulting or Advisory Role - Bayer Schering Pharma; Janssen |
Research Funding - Bayer Schering Pharma (Inst) |
Travel, Accommodations, Expenses - Bayer Schering Pharma; Janssen |
|
|
Honoraria - Astellas Pharma; Ipsen; Novartis |
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme (Inst); Pfizer |
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Pfizer |
|
|
No Relationships to Disclose |
|
|
Leadership - Aurora Oncology |
Stock and Other Ownership Interests - Aurora Oncology |
Honoraria - BN ImmunoTherapeutics; GTx |
Consulting or Advisory Role - GTX |
Research Funding - Agensys; Aragon Pharmaceuticals; Astellas Pharma; astrazeneca/MedImmune; Bavarian Nordic; Bristol-Myers Squibb; Cougar Biotechnology; Dendreon; Exelixis; GTx; Janssen Oncology; La Roche-Posay; Lilly; Medivation; Novartis; Pfizer; Roche/Genentech; Sanofi; Seagen; Sotio; Tokai Pharmaceuticals |
Patents, Royalties, Other Intellectual Property - The University of Colorado has filed 2 patents related in which I am an inventor. These are related to early-stage bladder cancer treatment and detection. Neither is commercialized or licensed at this time. |
Travel, Accommodations, Expenses - Bavarian Nordic; GTx |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Johnson & Johnson; Pfizer; Sanofi |
Speakers' Bureau - Bayer; Johnson & Johnson |
|
|
Leadership - Large Urology Group Practice Association |
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Dendreon; Ferring; Genentech/Roche; Janssen Scientific Affairs; Medivation/Astellas; Myovant Sciences; Pfizer; Sanofi; Tolmar |
|
|
No Relationships to Disclose |
|
|
Employment - Bavarian Nordic |
Leadership - Bavarian Nordic |
Stock and Other Ownership Interests - Bavarian Nordic |
|
Consulting or Advisory Role - MPM Capital |
Travel, Accommodations, Expenses - Bavarian Nordic; MPM Capital |
|
|
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; CureVac; Janssen-Cilag; Merck Sharp & Dohme; Sanofi |
Speakers' Bureau - Merck Sharp & Dohme |
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen-Cilag (Inst) |
Travel, Accommodations, Expenses - Amgen; Bayer; Merck Sharp & Dohme |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; Context Therapeutics; Druggablity Technologies; Placon; Seer; Tarveda Therapeutics |
Consulting or Advisory Role - Bavarian Nordic; BIND Biosciences; Context Therapeutics; Druggablity Technologies; GE Healthcare; Genentech/Roche; Janssen; Merck; Metamark Genetics; New England Research Institutes; OncoCellMDX; Progenity; Sanofi; Seer; Tarveda Therapeutics; Thermo Fisher Scientific |
Patents, Royalties, Other Intellectual Property - Chromosome Copy Number Gain as a Biomarker of Urothelial Carcinoma Lethality; Composition and Methods for Screening and Diagnosis of Prostate Cancer; Drug Combinations to Treat Cancer; Method for Predicting the Risk of Prostate Cancer Morbidity and Mortality; Methods and Kits for Determining Sensitivity to Cancer Treatment; Methods for Predicting Likelihood of Responding to Treatment; Predicting and Treating Prostate Cancer; Somatic ERCC2 Mutations Correlate with Cisplatin sensitivity in muscle-invasive Urothelial Carcinoma (Patent); Up-to-Date Royalties; Wolters Kluwer Royalties |
Expert Testimony - Janssen |
Travel, Accommodations, Expenses - Sanofi |